Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment Long-term tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active l...

• Country Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
• organs None
• Specialty None

Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep...

• Country None
• organs None
• Specialty None

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment This study is to evaluate change of over active bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.

• Country Korea, Republic of
• organs None
• Specialty None

Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat ...

• Country Belgium, Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Portugal, Spain, United Kingdom
• organs None
• Specialty None

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid

• Country None
• organs None
• Specialty None

A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients A proof of concept study to evaluate the safety and effectiveness of FK778 in liver transplant patients.

• Country Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Spain, Switzerland, United Kingdom
• organs None
• Specialty None